OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.
OncoCyte believes Razor's CLIA-validated lung cancer prognostic test will complement its in-development DetermaVu lung cancer detection assay.
Addenbrooke' Hospital will manage and facilitate the fulfillment orders of the firm's PredictSure IBD orders, as well as receive and process all samples.
By achieving certification for the assay, called PredictSure IBD, the Cambridge, UK-based firm can sell it for clinical use across Europe.
The company aims to commercialize ProstaGene's PCaTest, which uses a 16-gene panel to determine the overall outcome of a patient's prostate cancer.
In a new analysis of the trial, researchers concluded that women over the age of 50 with recurrence scores below 25 appear to see no added benefit from adjuvant chemo.
Unicancer will provide patients with centralized laboratory testing performed by Agendia, and also adopt the company's NGS kits for decentralized testing.
Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The levels of the metabolite could predict near- and long-term cardiovascular events or death, the research team reported.